Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dicks Sporting Goods Inc (DKS) vs Moderna, Inc. (MRNA) Price & Performance

Dicks Sporting Goods IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Dicks Sporting Goods Inc vs Moderna, Inc. — how do they compare? Dicks Sporting Goods Inc trades at $203.52 (market cap $18.35B), while Moderna, Inc. trades at $63.93 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

DKSMRNA
Market Cap
$18.35B$24.18B
Sector
Consumer CyclicalHealth
52-Week High
$239.17$81.80
52-Week Low
$187.78$22.36
Enterprise Value
$25.14B$20.33B
Dividend Yield
2.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dicks Sporting Goods Inc

Dick's Sporting Goods (DKS) trades at $201.95, down 5.67% in the past 24 hours, with technical indicators showing a bearish trend and key support at $198. Fundamentally, the company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $2.90 beating expectations, and maintains solid profitability with a 32.21% gross margin and 20.9% ROE. Recent news highlights analyst upgrades and positive coverage, while the company announced a $1.25 dividend payable in June 2026.

The outlook for DKS is mixed; analyst consensus is bullish with a $263.22 price target and no sell ratings, but technical weakness and a recent decline pose near-term risks. Investment opportunities include undervaluation based on a P/E of 19.96 and accelerating sales growth, while risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder litigation news.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA